Change search
ReferencesLink to record
Permanent link

Direct link
Circulating Carnosine Dipeptidase 1 associates with weight loss and poor prognosis in gastrointestinal cancer
KTH, School of Biotechnology (BIO), Proteomics and Nanobiotechnology.
KTH, School of Biotechnology (BIO), Proteomics and Nanobiotechnology.ORCID iD: 0000-0001-8141-8449
KTH, School of Biotechnology (BIO), Proteomics and Nanobiotechnology.
Show others and affiliations
2015 (English)In: PLoS ONE, ISSN 1932-6203, Vol. 10, no 4, e0123566Article in journal (Refereed) Published
Abstract [en]

Background: Cancer cachexia (CC) is linked to poor prognosis. Although the mechanisms promoting this condition are not known, several circulating proteins have been proposed to contribute. We analyzed the plasma proteome in cancer subjects in order to identify factors associated with cachexia. Design/Subjects: Plasma was obtained from a screening cohort of 59 patients, newly diagnosed with suspected gastrointestinal cancer, with (n = 32) or without (n = 27) cachexia. Samples were subjected to proteomic profiling using 760 antibodies (targeting 698 individual proteins) from the Human Protein Atlas project. The main findings were validated in a cohort of 93 patients with verified and advanced pancreas cancer. Results: Only six proteins displayed differential plasma levels in the screening cohort. Among these, Carnosine Dipeptidase 1 (CNDP1) was confirmed by sandwich immunoassay to be lower in CC (p = 0.008). In both cohorts, low CNDP1 levels were associated with markers of poor prognosis including weight loss, malnutrition, lipid breakdown, low circulating albumin/IGF1 levels and poor quality of life. Eleven of the subjects in the discovery cohort were finally diagnosed with non-malignant disease but omitting these subjects from the analyses did not have any major influence on the results. Conclusions: In gastrointestinal cancer, reduced plasma levels of CNDP1 associate with signs of catabolism and poor outcome. These results, together with recently published data demonstrating lower circulating CNDP1 in subjects with glioblastoma and metastatic prostate cancer, suggest that CNDP1 may constitute a marker of aggressive cancer and CC.

Place, publisher, year, edition, pages
2015. Vol. 10, no 4, e0123566
Keyword [en]
albumin, carnosine dipeptidase 1, dipeptidase, somatomedin C, unclassified drug, adult, Article, blood analysis, cachexia, cancer prognosis, catabolism, clinical article, cohort analysis, controlled study, digestive system cancer, disease association, enzyme blood level, enzyme immunoassay, female, glioblastoma, human, male, malnutrition, metastasis, outcome assessment, prostate cancer, proteomics, quality of life, validation process, weight reduction
National Category
Medical and Health Sciences
URN: urn:nbn:se:kth:diva-167745DOI: 10.1371/journal.pone.0123566ISI: 000353212600032ScopusID: 2-s2.0-84928571516OAI: diva2:815529
Swedish Research CouncilKnut and Alice Wallenberg FoundationSwedish Cancer SocietyNovo NordiskSwedish Diabetes AssociationSwedish Heart Lung Foundation

QC 20150601

Available from: 2015-06-01 Created: 2015-05-22 Last updated: 2015-06-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textScopus

Search in DiVA

By author/editor
Henjes, FraukeSchwenk, Jochen M.Darmanis, Spyros N.Nilsson, Peter M.
By organisation
Proteomics and Nanobiotechnology
In the same journal
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 49 hits
ReferencesLink to record
Permanent link

Direct link